Ausgabe 3/2023
Inhalt (8 Artikel)
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Dongxue Liu, Linlin Hu, Hua Shao
Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer
Gaoqi Xu, Dihong Yang, Chaoneng He, Like Zhong, Junfeng Zhu, Qi Shu, Haiying Ding, Wenxiu Xin, Yinghui Tong, Xiao Zhu, Luo Fang
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P. Safran, Laura Nadeau, William J. Edenfield, Lionel D. Lewis, Lone H. Ottesen, Yan Li, Ganesh M. Mugundu
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
Nastya Kassir, Phyllis Chan, Steve Dang, René Bruno
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo
Dongbo Wang, Huina Wu, Qian Wu, Qi Liu, Yamei Li, Jiyong Wu, Jing Nie
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab
Emmanuelle Jacquet, Fiona Pham, Billy Taouk, Ghania Kerouani-Lafaye, Adrien Monard, Liora Brunel, Nicolas Albin
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
M. Valery, K. Saleh, R. Ecea, J. M. Michot, V. Ribrag, K. Fizazi, A. Hollebecque, A. Lecesne, S. Ponce, Y. Loriot, S. Champiat, C. Baldini, C. Sarkozy, C. Castilla-Llorente
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series
Taro Yamanaka, Kohji Takemura, Michikata Hayashida, Koichi Suyama, Shinji Urakami, Yuji Miura